You are here

diabetes

Novo's high-dose Rybelsus win tees up regulatory filings—and new rivalries

Novo's high-dose Rybelsus win tees up regulatory filings—and new rivalries

Fierce Pharma

clinical trials

Flag link:

The Ozempic Obesity Battle Is Heating Up With Novo Scoring A Fresh Win

The Ozempic Obesity Battle Is Heating Up With Novo Scoring A Fresh Win

Investors Business Daily

Flag link:

Most-clicked pharma news for week ending March 25: PTC Therapeutics CEO retires and Novartis' Zolgensma shows sustained efficacy

Most-clicked pharma news for week ending March 25: PTC Therapeutics CEO retires and Novartis' Zolgensma shows sustained efficacy

CP Wire

PTC Therapeutics

Flag link:

Most-clicked pharma news for week ending March 25: PTC Therapeutics CEO retires and Novartis' Zolgensma shows sustained efficacy

PTC Therapeutics

Flag link:

In insulin resistance pact, Dewpoint adds Novo Nordisk to its pharma-rich pipeline

In insulin resistance pact, Dewpoint adds Novo Nordisk to its pharma-rich pipeline

Enpoints

Dewpoint Therapeutics

insulin resistance

Flag link:

Six-month Ozempic shortage mostly over after weight-loss craze drained supply

Six-month Ozempic shortage mostly over after weight-loss craze drained supply

Seattle Times, WA

Flag link:

California takes another step forward in its insulin production with $50M investment

California takes another step forward in its insulin production with $50M investment

Endpoints

Flag link:

Merck, Viatris agree to settle patent feud surrounding diabetes drugs

Merck, Viatris agree to settle patent feud surrounding diabetes drugs

Endpoints

Flag link:

Three's company: Sanofi follows lead of Lilly and Novo, slashes insulin price by 78% and caps out-of-pocket costs

Three's company: Sanofi follows lead of Lilly and Novo, slashes insulin price by 78% and caps out-of-pocket costs

Endpoints

Flag link:

Strategy Behind Lowered Insulin Prices: Novo Nordisk and Eli Lilly

Strategy Behind Lowered Insulin Prices: Novo Nordisk and Eli Lilly

BioSpace

Flag link:

Bayer study finds communication gap in managing chronic kidney disease in patients with type 2 diabetes

Bayer study finds communication gap in managing chronic kidney disease in patients with type 2 diabetes

Medical Marketing and Media

chronic kidney disease

healthcare providers

Flag link:

Novo Nordisk Will Lower Insulin Prices Up To 75%, Following Eli Lilly

Novo Nordisk Will Lower Insulin Prices Up To 75%, Following Eli Lilly

Forbes

Flag link:

CRISPR/ViaCyte and Genprex Vie for First Diabetes Gene Therapy

CRISPR/ViaCyte and Genprex Vie for First Diabetes Gene Therapy

BioSpace

CRISPR Therapeutics

Flag link:

Sanofi throws down $2.9B to acquire diabetes partner Provention Bio

Sanofi throws down $2.9B to acquire diabetes partner Provention Bio

Fierce Pharma

Flag link:

Eli Lilly kicks off consumer campaign for diabetes drug Mounjaro

Eli Lilly kicks off consumer campaign for diabetes drug Mounjaro

Medical Marketing and Media

Flag link:

Why does insulin cost so much? Big Pharma isn’t the only player driving prices

Why does insulin cost so much? Big Pharma isn’t the only player driving prices

Medical Marketing and Media

Flag link:

8 Moments that Defined Diabetes Tech

8 Moments that Defined Diabetes Tech

Medical Devices and Diagnostics Industry

Flag link:

Abbott Scores a 'Long-Awaited Win' in Diabetes

Abbott Scores a 'Long-Awaited Win' in Diabetes

Medical Devices and Diagnostics Industry

Freestyle Libre 2

FreeStyle Libre 3

Flag link:

Lilly to cut insulin prices by 70%, cap prices at $35 per month for people with private insurance

Lilly to cut insulin prices by 70%, cap prices at $35 per month for people with private insurance

CNBC

Flag link:

Should Abbott and DexCom Investors Be Worried About Apple's Latest News?

Should Abbott and DexCom Investors Be Worried About Apple's Latest News?

Motley Fool

continuous glucose monitoring

Flag link:

Pages